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Abstract
Objective:  To review the classification, evaluation, and management of pediatric urinary incontinence.
Methods: An examination of texts and peer-reviewed literature was performed to identify subject matter
relevant to the stated objectives, with the experience of the senior author used in cases where the literature
failed to provide guidance.
Results: On the basis of our review, we identified the International Children’s Continence Society’s (ICCS)
statement standardizing the terminology for lower urinary tract function in children and present a logical
classification scheme for incontinence. After an epidemiology review, we discuss the appropriate evaluation
of the incontinent child, of which the cornerstones are a detailed history and thorough physical exam.
Finally, a concise discussion of the management of daytime incontinence, nocturnal enuresis, and neurogenic
and anatomic incontinence is presented, with deference to evidence-based approaches where available.
Depending on the type of incontinence, the management strategies can include behavioral, pharmacologic,
and/or surgical approaches.incon
gical Surgeons’ Association. Production and hosting by Elsevier B.V. 
s Continence Society; PVR, postvoid residual (urine); MNE, monosymptomatic
, United States Food and Drug Administration; LUTS, lower urinary tract
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Table  1  General classification of urinary incontinence.
Anatomic Congenital
Ectopic ureter
Bladder exstrophy-epispadias complex
Persistent urogenital sinus with high genitourinary
confluence
Urethral duplication
Acquired
Iatrogenic injury to external urethral sphincter (e.g.
after posterior urethral valve ablation or ectopic
ureterocele excision)
Neurologic Congenital
Myelodysplasia
Occult spinal dysraphisms
Sacral agenesis
Acquired
Central nervous system lesion (e.g. cerebral palsy,
tumor, radiation, stroke, multiple sclerosis)
Peripheral nervous system injury (e.g. injury to
pelvic plexus and bladder efferents/afferents)
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he purpose of this article is to introduce the up-to-date nomen-
lature for pediatric urinary incontinence after which a general
ramework to guide the practitioner in classifying, evaluating, and
anaging an incontinent child is provided. A detailed discussion
f the pathologic processes and long-term management of specific
onditions causing incontinence is outside the scope of this review.
efinitions and  classification
rinary incontinence (UI) is any involuntary or uncontrollable
eakage of urine [1]. As urinary incontinence can be present in a
ariety of situations, the International Children’s Continence Soci-
ty (ICCS) has unified the definitions and terminology of pediatric
rinary incontinence and lower urinary tract symptoms [1]. Con-
inuous incontinence  refers to constant leakage of urine and can
ccur even in infants and young children. Intermittent  incontinence
s defined as any urine leakage in discrete amounts in a child at
east 5 years old. When a child has never been dry of urine, they
ave primary  incontinence. However, if a child becomes inconti-
ent after a previous period of good urinary control, they have
econdary incontinence. When intermittent incontinence occurs
hile the child is awake, it is called daytime  incontinence. Con-
ersely, when occurring while asleep it is described as enuresis  or
octurnal enuresis, which are synonymous terms. When enuresis
ccurs in isolation, that is when there is no history of lower urinary
ract symptoms (except nocturia), it is defined as monosymptomatic
octurnal enuresis (MNE). Children with enuresis and any other
ower urinary tract symptoms (LUTS) are defined as having non-
onosymptomatic nocturnal enuresis (NMNE). These LUTS can
e daytime incontinence, urgency, frequency, dysuria/stranguria, or
thers. When bedwetting occurs in a child with concomitant daytime
ower urinary tract symptoms causing incontinence, the child has a
ual diagnosis of nocturnal enuresis with daytime urinary inconti-
ence. Urge  incontinence  refers to urinary leakage resulting from
rgency. Giggle  incontinence  is an unusual phenomenon most often
ound in girls in which nearly complete voiding occurs during or
mmediately after laughing. The use of terms ‘total incontinence’
nd ‘diurnal enuresis’ is discouraged. The former term is replaced by
ontinuous incontinence, whereas children with both daytime and
ighttime incontinence, formerly described as ‘diurnal enuresis’,
ave a dual diagnosis – daytime incontinence and nocturnal enuresis.
eurologically intact children with urodynamically proven inter-
ittent voluntary contractions of the external urethral sphincter or
elvic floor during voiding are said to have dysfunctional  voiding.
hildren with urinary incontinence will be found to have one of
hree etiologies for their incontinence (Table 1). Anatomic lesions
an lead to continuous incontinence, a vital clue that can be elicited
rom the history and examination. In females, ectopic ureters with
rifices distal to the external urinary sphincter will cause continu-
us incontinence, as do the sphincteric deficiencies seen in children
ith epispadias, bladder and cloacal exstrophy. Treatment for other
ongenital urinary tract anomalies such as posterior urethral valves
nd ectopic ureteroceles can damage the normal sphincter control
echanisms and secondarily cause urinary incontinence.eurologic lesions in the brain, spinal cord, or autonomic and/or
omatic peripheral nervous system(s) can result in incontinence.
he most common cause of neurogenic bladder dysfunction in
k
d
i
sFunctional Daytime incontinence
Nocturnal Enuresis
hildren is myelodysplasia [2], a term used to describe various
bnormalities resulting from failed fusion of the vertebral column
ith associated malformations of the spinal cord and surround-
ng structures. More specifically, myelodysplastic patients can have
 protrusion of the meninges with intact spinal cord elements
meningocele), protrusion of spinal cord elements with the meninges
myelomeninogocele), or evagination of fat, meninges, and spinal
ord elements (lipomyelomeningocele). Occult spinal dysraphisms
re conditions such as fatty filum terminale, intramedullary lipoma,
eurenteric cysts, terminal syringohydromyelia with subtle skin
efects and physical findings like midline nevi, hemangioma, lower
idline hairy patch, or an assymetric gluteal cleft that can suggest
 tehtered spinal cord as a cause for urinary incontinence. Occult
pinal dysraphisms are distinct from spina bifida occulta, which is
he mildest type of vertebral bony defect in which the sacrum has
ailed to fuse in the midline but does not involve the spinal cord or
ura. Spina bifida occulta is an incidental finding as patients have
o symptoms.
hile spinal dysraphisms may be the most common cause of neu-
ogenic pediatric urinary incontinence, any acquired condition that
nterrupts the normal cortical control mechanism, spinal pathways,
r bladder efferents and afferents can result in neurogenic urinary
ncontinence. The conditions that cause this are wide and varied,
ut some examples include: hypoxic insults like cerebral palsy or
ediatric strokes affecting the brainstem or higher urinary con-
rol centers, brain or spinal cord tumors that primarily or as a
esult of their treatment result in incontinence, and radical pelvic
urgery for congenital anomalies (e.g. a ‘pull-thru’ operation for
mperforate anus) or cancers (e.g. a radical pelvic exenteration for
habdomyosarcoma) that damage peripheral autonomic or somatic
erves and sacrifice continence.
inally, functional incontinence can occur in children without any
nown anatomic or structural neurologic lesions. The etiology of
aytime incontinence and nocturnal enuresis is varied. Urinary tract
nfections can cause inflammation and irritation that lead to tran-
ient incontinence. Children can have behavioral issues such as urine
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holding that leads to detrusor overactivity and/or overflow inconti-
nence. Detrusor overactivity has also been implicated in nocturnal
enuresis, as have lower than normal levels of nocturnal vasopressin
secretion and impaired sleep arousal patterns [3–5]. Mood disor-
ders such as attention deficit hyperactivity disorder and anxiety as
well as conduct disorders are frequent comorbidities encountered in
children with UI [6–8], as is constipation [9,10]. Previously conti-
nent children experiencing a stressful life event such as the divorce
of parents or loss of a sibling can develop secondary incontinence
[11,12].
Epidemiology
Pediatric urinary incontinence is a common disorder affecting
children of all ages and cultures. Unfortunately due to their
population-based nature, most studies addressing the prevalence of
pediatric UI do not classify by the etiology of incontinence, yet they
are still helpful in understanding the prevalence of urinary inconti-
nence in general. A sample of 1192 three to twelve year old children
from the United States identified daytime incontinence in 10% of
children [13]. Kajiwara identified daytime incontinence in 6.3%
of seven to twelve year old Japanese primary school children and
affected males and females equally [14]. Sureshkumar performed a
population based survey and found that 19.2% of school age chil-
dren had experienced daytime UI at least once in the 6 months
prior to survey, with a higher prevalence in females than males [15].
Another Australian study of five to twelve year old school children
identified a prevalence of 2% for isolated daytime UI and 4% for
daytime incontinence and nocturnal enuresis [16]. Similarly, 6% of
school age girls and 3.8% of school age boys had daytime UI in one
Swedish study [17].
Enuresis is also highly prevalent. In a study of 10,960 children in the
United States, nocturnal enuresis was found in boys at seven and ten
years was 9% and 7%, respectively, and in girls at those ages was
6% and 3% [18]. Bloom identified enuresis in 18% of another US
sample, though the median age was lower [13]. A large population
based study in Great Britain suggested that 20% of children in the
first grade occasionally wet the bed [19]. Given the prevalence of
pediatric UI and associated symptoms, it is not surprising that it
represents 7% and 40% of general pediatric outpatient referrals and
pediatric urology visits, respectively [20,21].
As mentioned, no population-based studies investigating the preva-
lence of pediatric UI do so by their specific etiologies. It is reasonable
to conclude from clinical experience and from the relative rar-
ity of anatomic and neurologic causes that the largest proportions
of children with urinary incontinence do not have organic causes.
Nevertheless, it is always prudent to consider these etiologies in the
initial evaluation and subsequent management of the incontinent
child.
Evaluation
A detailed history and physical exam are the cornerstones of the
evaluation of pediatric urinary incontinence and guide which tests,
if any, should be considered. Table 2 shows the evaluation tools
available to the clinician faced with an incontinent child.
The history should be broad yet specific and include information
from the child as well as the caregiver/parent. Detailed information
t
o
[
u3
egarding when (daytime or nighttime), where (at school/public
lace and/or at home), how often (once a week or daily), and how
uch (small or large volume) leakage occurs is important, as is
nformation pertaining to bowel habits, with a determination of the
requency and consistency of bowel movements and presence of any
owel accidents. Frequency-volume charts (i.e. voiding diaries) can
e helpful in gathering this information about voiding and elimina-
ion habits. The provider should identify if the child has had any
revious operations including but not limited to abdominal, gen-
tourinary, and pelvic surgery. Knowing whether there was ever
 period of complete urinary control in a child of toilet-trained
ge can help distinguish between primary and secondary inconti-
ence. Details of the perinatal history are important, as are questions
ocused on the child’s gross and fine motor and behavioral devel-
pment. Motor impairments could suggest underlying spinal cord
athology also affecting the lower urinary tract. School performance
nd behavior should be queried. As attention deficit hyperactivity
isorder has been associated with urinary incontinence, one should
sk whether the teacher has noted the child to be easily distracted or
as problems with impulsivity. Conversely, high achieving children
ho are very focused on school performance can acquire voiding
ostponement and urge incontinence and should thus be identified.
he provider should query whether there is any evidence of stressors
t home such as parental conflict or recent losses that could cause
evelopmental regression and secondary incontinence. Importantly,
nformation should be obtained regarding any history of urinary tract
nfections.
ike a detailed history aimed at identifying clues toward the etiology
f a child’s incontinence, a focused physical exam can shed light on
he etiology as well as direct testing. The gross motor function of a
hild can simply be observed as he/she walks into the examination
uite. An abdominal exam assessing for abdominal masses, a stool
lled colon, or distended bladder should be performed. The integrity
f the lower abdomen and pubic symphysis should be assessed.
n girls, the genital exam should note the presence and relation of
he urethra to the vaginal and rectal orifices. A patulous urethra in
 girl with a widened pubic diastasis suggests female epispadias.
bservation of pooling urine in the vaginal introitus is an important
lue that an ectopic ureter might be present. The child’s back should
e examined, with particular attention paid to recognizing signs of
ccult spinal dysraphism (hairy tufts, subcutaneous lipomas, skin
iscoloration, or sacral dimples above the gluteal cleft) and tethered
ord (asymmetric gluteal fold). The neurological exam should assess
ower extremity reflexes, perineal sensation, anal tone and reflex, and
he presence of the bulbocavernosus reflex.
he history and physical exam will provide important clues as to
hich additional tests will help further identify the cause of urinary
ncontinence. A urinalysis should be performed in most cases, as
nfection (bacteriuria, pyuria, hematuria), renal damage with high
rine output (proteinuria, low specific gravity), or diabetes (gluco-
uria) as a cause for osmotic diuresis can be identified. An easy
est to add to any physical exam that gives important information
egarding bladder emptying is a bladder scan with postvoid residual
PVR) measurement. This will aid the provider in knowing how well
he child empties, and can prompt further studies when large PVRs
re found on successive tests. Most children should be able to empty
o 5 cm3 or less, whereas repeated residual measurements of 20 cm3
r more are concerning for pathology in the bladder and/or urethra
1]. When discovered, high PVRs could require renal and bladder
ltrasound, voiding cystourethrogram, and/or urodynamic studies
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Table  2  Diagnostic options and their indications in the workup of pediatric urinary incontinence.
Diagnostic option Indications Comments Findings
History • All patients • Helps guide practioner towards neurogentic,
anatomic, or functional incontinence
Physical exam • All patients • Helps guide practioner towards neurogentic,
anatomic, or functional incontinence
Urinalysis • All patients • Bacteruria/pyuria: infection
• Proteinuria: kidney damage with possible high urine output
•  Glucosuria: diabetes mellitus with possible osmotic diuresis
Bladder scan with postvoid
residual  (PVR) measurement
• All patients • Not necessary if planning to order RBUS • PVR consistently > 20 ml on several measures needs workup
to identify if neurogenic, myogenic, or anatomic cause is
present
Uroflowmetry • Most patients • Can include EMG if full urodynamics not planned See Fig. 1
Renal and bladder ultrasound
(RBUS)
• Most patients • Provides functional information (estimated bladder
capacity, bladder emptying/postvoid residual, bladder
wall thickness)
•  Identifies gross upper and lower urinary tract pathology
•  Identifies constipation
• Renal scarring suggests vesicoureteral reflux (VUR)
•  Dilatation of ureter and duplicated upper tract suggestive of
ectopic ureter
•  Thickened bladder indicates high voiding pressures from
distal obstruction (anatomic – PUV; neurologic –
detrusor-sphincter dyssynergia)
Abdominal radiography • Most patients • Identifies gross bony anomalies
• Identifies constipation
Urodynamics • Failed medical or behavioral therapy
• Suspected neurogenic pathology
•  Storage measurements include: maximum bladder
capacity, Pdet at bladder capacity, detrusor leak point
pressure, abdominal leak point pressure, bladder
compliance, detrusor overactivity
•  Emptying measurements include: uroflowmetry with
EMG, maximal Pdet during void, voided volume, PVR
• Identifies neurologic etiology
• Provides evidence to guide treatment
Spinal ultrasound • Suspected spinal pathology • Applicable in those < 6 months of age • Identifies spinal dysraphisms, tethered spinal cords, and other
occult spinal lesions associated with neurogenic incontinence
Spinal MRI  • Suspected spinal pathology • Applicable in those > 6 months of age
• Requires sedation in many children
•  Identifies spinal dysraphisms, tethered spinal cords, and other
occult spinal lesions associated with neurogenic incontinence
VCUG • Post-UTI
•  Suspected anatomic abnormality (e.g. ureterocele,
ectopic ureter, duplicated urethra)
•  Adolescent males with incontinence
• Identifies posterior urethral valves
• Identifies ectopic ureters with orifices at external urethral
sphincter
•  ‘Spinning top’ urethra indicative of dysfunctional voiding
Magnetic resonance imaging
(MRI)/urography  (MRU)
• Suspected anatomic pathology (e.g. ectopic ureter) • Requires sedation • Clarifies anatomy of ectopic ureters and their renal
component, Müllerian remnants, and other unusual anatomic
abnormalities
Cystoscopy • Rarely used in diagnosis of incontinence
• Appropriate when other diagnostic modalities
have not provided etiology of incontinence
•  Confirms findings of diagnostic imaging studies
Pediatric urinary incontinence 5
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Fig.  1  Examples of uroflowmetry in children. (A) Normal flow showing bell-shaped curve and cessation of external sphincter activity on EMG.
(B and C) Staccato shaped flow, which can occur with a weak or unsustained detrusor contraction but quiet external urethral sphincter (as in B) or
with periodic bursts of sphincter activity on EMG while voiding with a continuous but varying flow rate (as in C). To qualify as a Staccato pattern,
the fluctuations in flow should be larger than the square root of the maximal flow rate. (D) Interrupted or fractionated voiding notable for periods of
no urine flow in the absence of EMG activity. Like the Staccato pattern, this can occur with an unsustained detrusor contraction but also result when
voiding is achieved via abdominal muscle contractions in the presence of an acontractile bladder. (E) Plateau shaped flow showing low amplitude,
prolonged void and cessation of sphincter activity on EMG. This occurs as a result of a fixed anatomic obstruction or a weak detrusor contraction.
Plateau shaped flow can also occur with a tonically active external sphincter (not depicted). (F) Tower shaped flow with a high amplitude, short
duration of flow caused by detrusor overactivity; may result in urge incontinence. (G) Primary bladder neck dysfunction with urine flow beginning
at least 6 s after the cessation of sphincter activity on EMG.
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o elucidate if the high residual is from an anatomic, neurologic, or
unctional cause.
imilarly, a uroflow with external sphincter electromyography
EMG) is a test that can easily be done in the clinician’s office
hat can provide clues as to the coordination of pelvic floor during
icturition. The decision to exclude EMG from the uroflow can be
ade if a full urodynamic study (which includes external sphinc-
er EMG) is going to be performed. The EMG, whether obtained
uring uroflowmetry or a urodynamic study, provides critical addi-
ional information that can prevent incorrect diagnoses [22]. The
hild should be instructed to drink fluid in an amount equal to their
stimated bladder capacity 60 min prior to the test. Also, two tests
each with a voided volume between 50% and 100% of estimated
ladder capacity) should ideally be performed to account for vari-
bility between curves generated from the same individuals. As there
re no pediatric specific standardized flow rates, the pattern of the
ow curve is used to distinguish pathologic from non-pathologic
mptying. A normal flow curve should be bell-shaped (Fig. 1). A
taccato-like uroflow has peaks and troughs but a continuous urinary
tream. This can occur with a weak or unsustained detrusor contrac-
ion in the presence of a quiet EMG or with an adequate detrusor
ontracting against an active external sphincter, as seen in dysfunc-
ional voiding. An interrupted flow curve (fractionated voiding) has
eriods of zero flow in the absence of EMG activity, and can occur
ith an unsustained detrusor contraction or result when voiding is
chieved via abdominal muscle contractions in the presence of an
contractile bladder. A flat, plateau-like flow curve is suggestive
f either a fixed anatomic obstruction, a weak bladder contraction
from either a neurogenic or myogenic cause), or a tonically active
xternal sphincter. A high amplitude, short duration “tower-shaped”
ow curve is suggestive of detrusor overactivity potentially result-
ng in urge incontinence. Glassberg has used uroflow and EMG
o detect primary bladder neck dysfunction in those who’s time
etween pelvic floor relaxation and the initiation of urine flow (EMG
ag time) was greater than 6 s [23].
he renal and bladder ultrasound should be considered an appro-
riate non-invasive test in most children with urinary incontinence.
he ultrasound should be detailed enough to determine the presence
r absence of duplicated renal collecting system, renal morphology
nd scarring, upper tract dilatation, bladder capacity, and bladder
all thickening or irregularity. Both the upper and lower urinary
racts should be imaged with a full and empty bladder. A plain film
f the abdomen should be considered in most cases as well, with
articular attention directed towards identifying the amount of stool
n the colon, and the presence of any vertebral bony anomalies (pos-
ibly indicating a neurogenic cause of urinary incontinence) and/or
 widened pubic diastasis (possibly indicating a disorder along the
pispadias-exstrophy spectrum).
rodynamics with external urethral sphincter electromyography are
ndicated for those with a suspected or proven neurologic lesion
tethered cord on MRI, all patients with spina bifida, patients who
ave had radical abdominopelvic surgery), incontinent adolescent
ales with late diagnosis of posterior urethral valves, and in patients
ho fail behavioral or medical therapy. The specifics of the urody-
amics study are described in detail by MacLellen and Bauer [2].
riefly, the test includes an 11Fr triple lumen urodynamic catheter in
he bladder to measure intravesical pressure (Pves), a small balloon
atheter in the rectum to measure intrabdominal pressure (Pabd), and
ither a 24-gauge needle electrode placed into the skeletal muscle
m
w
i
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f the external urethral sphincter [24] or perineal patch electrodes
25] to measure external urethral sphincter activity. The detrusor
ressure (Pdet) is calculated by subtracting Pabd from Pves. These
easuring devices are connected to commercially available uro-
ynamic systems to record and display the measurements. Upon
nserting the urethral catheter, the bladder pressure should be noted.
he initial voiding opportunity allows uroflowmetry with EMG, the
etrusor and abdominal pressures during voiding, and the voided
nd residual urine volume to be measured. The bladder is then filled
ith warmed 37 degree saline at a rate equal to one-tenth of the
hild’s predicted or known capacity (capacity/10). Key measure-
ents taken during bladder filling and storage include the maximal
ladder capacity and its associated detrusor pressure, detrusor leak
oint pressure, presence of detrusor overactivity, whether leakage
ccurs with the increased abdominal pressure, and the volume at
rst leak. The instillation of radiopaque contrast medium instead
f saline together with fluoroscopic equipment enables videourody-
amics, or real-time visualization of the bladder neck and urethra
uring the voiding phase, to be performed.
everal other adjunctive tests can play key diagnostic roles when
ndicated. If the history and/or physical investigations suggest a
eurologic etiology, the spinal cord should be imaged to iden-
ify anomalies such as syringocele, cord tethering, or malposition,
mong others. Ultrasound can be used in those younger than 6
onths of age, owing to the fact that the vertebrae are not completely
ssified. In those older than 6 months of age, MRI is indicated to
etect vertebral and spinal cord pathology. A magnetic resonance
rography can be performed when there is a suspicion of or to help
efine the anatomy of an ectopic ureter or other anatomic cause of
ncontinence such as common cloaca, urogenital sinus, or anorectal
nomalies. A voiding cystourethrogram (VCUG) should be con-
idered in incontinent children with a history of febrile UTI and in
dolescent males with UI. In the former, unless an obstructed ectopic
reter is found to be entering into the external urethral sphincter in
irls, the VCUG is not likely to diagnose the cause of the urinary
ncontinence (which could be from the infection and inflamma-
ion causing temporary irritation to the bladder), but is important
o rule out vesicoureteral reflux and other sinister findings. How-
ver, a small proportion of males with posterior urethral valves will
resent in adolescence (owing to less severe disease or lack of prena-
al care), in which case the VCUG is diagnostic. Finally, in difficult
ases of incontinence, a cystoscopy can identify whether there is
rethral (such as a diverticulum, urethral duplication, or large pros-
atic utricle all which would lead to post-void dribbling), bladder
eck, or bladder pathology.
uestionnaires  developed  to  assess  incontinence
tandardized pediatric incontinence assessment tools nicely com-
lement the physician’s history and physical exam. These tools are
esigned to be filled out by the child or parent/caregiver as proxy
nd can be used at the initial intake as well as at subsequent visits to
elp track symptoms over the course of therapy. Some of these tools
ssess the symptoms and severity of lower urinary tract symptoms
LUTS) and urinary incontinence by incorporating urinary fre-
uency, urgency, the degree of wetness, and coexistent constipation
r bowel dysfunction into parent-proxy or child self-reported instru-
ents [26–28]. The Pediatric Incontinence Questionnaire (PIN-Q)
as designed to ascertain the effect of incontinence on a child’s qual-
ty of life [29]. The Bristol Stool Scale can be provided to patients
o determine the quality and character of their bowel movements
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[30]. There is great overlap in urinary symptoms measured with
these instruments, and no one questionnaire has been found to be
superior to another, such that the clinician should decide which one
(or two) instrument(s) captures the symptoms they desire while also
minimizing patient burden. Also, it is important to determine if the
selected questionnaire has been validated within a particular cul-
tural, social, and language context. Simple verbatim translation of a
questionnaire into another language is discouraged, as the meaning
of particular questions can be skewed because the cultural context in
which the survey was designed may differ from that of the intended
environment.
Management
A thorough history and physical exam with the addition of fur-
ther diagnostic tests, where indicated, will help determine if the
primary etiology is functional, neurologic, or anatomic. The man-
agement is then tailored to each type of incontinence, with some
overlap in medications and therapies between the former two types
of incontinence.
Functional  incontinence
a. Daytime  incontinence
It is important to emphasize to parents and children that many
patients with occasional daytime incontinence or enuresis will fall
within the normal developmental spectrum, and that their condition
is expected to improve over time. Nevertheless, owing in part to the
resultant psychosocial distress and family burden, many patients
and families will appropriately desire treatment.
As constipation is highly prevalent in this population [9], and
because its treatment has been shown to improve continence [31],
bowel management is a major priority in the management of chil-
dren with daytime incontinence, enuresis, and dysfunctional voiding
or dysfunctional elimination syndrome. Although the finding of
stool on abdominal film is indicative of constipation, the correlation
between the radiographic findings of stool and the degree of consti-
pation is weak. Nevertheless, the radiographic finding of more than
normal amounts of stool in the colon should provide strong enough
evidence to convince parents who insist that their child has ‘normal’
bowel movements.
A behavioral approach to bowel management is the first step. After
ensuring that the child is ingesting appropriate amounts of fiber and
drinking enough fluid, this approach consists of two or more daily
attempts at bowel movements. The child should sit on the toilet for
at least 5 min, even when evacuation attempts are unsuccessful. If
these conservative measures fail to show improvement, the addition
of polyethylene glycol 3350 (MiraLaxTM, GlycoLax) is often suc-
cessful. The recommended doses for constipation are 0.5–1.5 g/kg
daily titrated to effect, with a maximal dose of 17 g/day. However,
children can generally tolerate and may require much more than this.
Thus, 34–51 g (two to three capfuls) once daily dissolved in 240 mL
of water or juice with a sennosides oral laxative once a week can
be used for several months. Down titration begins approximately
six months later after consistently softer stools, more regular bowel
movements, and improvements on abdominal radiograph are noted.
Some patients will require a more aggressive bowel cleanout which
utilizes a large dose (two of more liters) of polyethylene glycol
3350 with balanced electrolytes (GoLytely®) given over 2 or 3 days,
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ith or without digital or pharmacologic (bisacodyl, glycerin) rectal
timulation.
he management of the bladder can begin after a bowel management
rogram, when indicated, has resulted in regular soft daily bowel
ovements. Bladder therapy proceeds in a stepwise fashion, and
an be suited to parental/caregiver preferences. Behavioral therapy
s a good starting point, the hallmark being the institution of a strict
very 2–3 h daytime voiding regimen after educating the child about
ormal bladder function and sensation. Children are also encouraged
o avoid caffeinated, carbonated, and highly acidic fluids. Voiding
iaries clarify for both the family and provider the evacuation habits,
nd need to include information regarding the time and the amount
f each void and/or leakage episode, time and consistency of each
owel movement, and amount of fluid intake. Aided by a normal
ladder cycling regimen, the goal of behavioral therapy is to re-
ducate the child about normal bladder sensation and garner central
ontrol to suppress bladder urges.
omplementing behavioral therapy is biofeedback therapy, which
rovides visual and auditory feedback to children about the external
rethral sphincter and pelvic floor bioactivity during bladder fill-
ng and emptying. Programs and games integrated with pelvic floor
ehabilitation are then used to teach children how to respond to nor-
al bladder urges during storage and promote pelvic floor relaxation
uring bladder and bowel elimination, thus targeting detrusor over-
ctivity and dysfunctional voiding, respectively. Although there are
o randomized controlled trials assessing the efficacy of biofeed-
ack therapy, one observational study showed improvement in 89%
nd 90% of children with daytime incontinence and nocturnal
nuresis [32]. Constipation was improved in 100% and resolved
ompletely in 33%. Biofeedback therapy is undertaken over sev-
ral sessions, with specialists in pediatric urology coaching the
atients through the process. This option requires the commitment
f families to attend several sessions and an attentive and motivated
hild.
hile behavioral and biofeedback therapy are good non-invasive,
on-pharmacologic methods to treat urinary incontinence, phar-
acologic therapy plays an important role in pediatric voiding
ysfunction, particularly among patients who do not respond to or
annot participate in more conservative approaches.
ral anticholinergic therapy is used for the treatment of overactive
ladder and urge incontinence (Table 3). Although several anti-
holinergics are used off-label in children with UI, only oxybutynin
s approved by the United States Food and Drug Administration
FDA) for use in this population. Both M2 and M3 muscarinic recep-
ors are found in the bladder, but the M3 subtype’s stimulation results
n direct detrusor contraction and micturition [33]. In blocking these
eceptors, anticholinergics mitigate the impact of uninhibited blad-
er contractions and increase bladder capacity, thereby decreasing
ncontinence episodes and increasing the time between and vol-
me of each voiding episode. The side effects of anticholinergic
rugs include dry mouth, blurred vision, facial flushing, headache,
iredness, gastrointestinal discomfort, and constipation. The degree
o which these side effects are apparent depends on the specificity
f the selected anticholinergic. Oxybutynin is known to decrease
weating, thus causing heat intolerance and overheating during
he summer as well as preventing some athletes from tolerating
his drug while engaged in sport. Although no short term memory
eficits were found in children taking oral anticholinergics [34],
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Table  3  Commonly used medications to treat pediatric urinary incontinence.
Medication Dosage Indication and notes
Anticholinergics • Urge incontinence from detrusor overactivity
Oxybutynin (Ditropan) 0.2 mg/kg bid–0.2 mg/kg qid • Transdermal route of administration allows for post-operative use
when awaiting return of bowel function and avoids initial first-pass
metabolism, potentially reducing side effects
• Intravesical administration touted to reduce systemic side effects, but
no Level I evidence supports this
• Only anticholinergic FDA approved for use in children
Tolterodine (Detrol)a 0.01 mg/kg bid–0.04 mg/kg bid
Hyoscyamine (Levsin)a 0.03 mg/kg bid–0.1 mg/kg tid
Trospium (Sanctura)a 10–20 mg/day
Solifenacin (Vesicare)a 5–10 mg/day • Better M3 selectivity purportedly reduces side effects compared to
oxybutynin, tolterodine, and trospium
Darifenacin (Enablex)a 7.5–15 mg/day • Better M3 selectivity purportedly reduces side effects compared to
oxybutynin, tolterodine, and trospium
Alpha-sympathomimetics • Low abdominal leak point pressure or urethral pressure profile
Ephedrinea 0.5 mg/kg bid–1 mg/kg tid
Pseudoephedrinea 0.4 mg/kg bid–0.9 mg/kg tid
Alpha-adrenergic receptor
antagonists
•  Primary bladder neck dysfunction
Tamsulosin (Flomax)a 0.4 mg/day
Doxazosin (Cardura)a 0.5 mg-2 mg/day
Alfuzosin (Uroxatral)a 10 mg/day
Terazosin (Hytrin)a 1–20 mg/day
Antidiuretics  • Enuresis
Desmopressin 0.2–0.4 mg/night • Controls but does not cure enuresis
• Compared to imipramine: no difference in efficacy, more expensive,
no anticholinergic side effects
•  Intranasal formulation not approved for enuresis
Tricyclic antidepressants • Enuresis
Imipramine 25–50 mg/night • Controls but does not cure enuresis
• Compared to desmopressin: no difference in efficacy, cheaper, higher
side effect profile
Neurolytics • Neurogenic and non-neurogenic detrusor overactivity in patients not
responding to conventional therapy
Onabotulinum toxin – Type A
(Botox)a
10–12 IU/kg diluted in 30 ml
normal saline, max 300 IU
• App. 30 trigone-sparing submucosal injections (1 ml each) under
cystoscopic guidance
•  Repeat injections needed after 3–12 months to sustain effect
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ne study noted hyperactivity, insomnia, and agoraphobia in a neu-
ogenic population being administered intravesical oxybutynin [35].
atients with concomitant constipation should be thoroughly evacu-
ted and maintained on an effective bowel regimen before initiating
nticholinergic therapy.
here are few randomized controlled trials assessing the efficacy
f oral anticholinergics in children with daytime incontinence. One
tudy compared oxybutynin to biofeedback therapy and placebo,
nd found no difference in the number of incontinent episodes after
ine months of follow-up [36]. Even with the paucity of Level 1
vidence demonstrating their efficacy, the apparent clinical effec-
iveness of oral anticholinergics support their use in this population.
ther oral pharmacotherapies can be selected based on specific eti-
logies of daytime incontinence. Alpha sympathomimetics such
s ephedrine or pseudoepherine can be used to target the bladder
eck and external urethral sphincter in patients with low abdominal
eak point pressures and intrinsic sphincter deficiency, though this
o
n
d
tng.
pproach has not been rigorously studied. Alpha-adrenergic recep-
or antagonists, first described by Austin and colleagues in 1999
37], can be selected for young males felt to have urinary incon-
inence that results for primary bladder neck dysfunction. These
ndividuals have impaired relaxation of the bladder outlet which
s evidenced by a delay of longer than 6 seconds between external
phincter relaxation and the initial urine flow as seen on uroflowme-
ry with EMG [23]. As these medications are used off-label for this
ndication, there is limited data regarding their optimal doses and
ide effect profiles in children. However, one recent study found no
dverse blood pressure effects in children given tamsulosin in adult
oses [38]. It is recommended to start patients at the lowest adult
ose for a particular agent, with titration as needed. Several obser-
ational studies have shown improvements in PVR, uroflowmetry,
nd/or EMG lag time with alpha blocker treatment [23,38,39]. The
ne randomized controlled trial of doxazosin versus placebo found
o difference in PVR or uroflow measurements, although the study
esign did not call for dose escalation and the study may have been
oo small to detect a difference in efficacy [40].
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Intravesical onabotulinum toxin – A (BTX-A, Botox) has been used
off-label in the treatment of overactive bladder in children with
primarily neurogenic and but also non-neurogenic urinary incon-
tinence. A potent but temporary neurotoxin, botulinum blocks the
release of acetylcholine from presynaptic nerve terminals, preven-
ting the stimulation of muscarinic receptors in the detrusor muscle
and subsequent bladder contraction. With cystoscopic guidance
under general anesthesia, injections of a 10 U/ml suspension are
placed submucosally throughout the bladder, sparing the trigone.
This medication is not FDA-approved for use in children, so dose
and efficacy data are sparse. Typically, doses are 10–12 U/kg with
a maximal dose of 300 U (equating to 30 injections of 10 U/ml)
[41]. The duration of effect ranges from 3 to 12 months, with
repeated injections needed to maintain the clinical effect [42–44].
There are no randomized controlled trials comparing this agent to
placebo or other oral therapeutics. Hoebeke injected 100 U into 21
neurologically intact children resistant to standard treatment, and
demonstrated a 60% complete and 20% partial improvement in urge
and daytime incontinence after one injection among the 15 children
with at least 6 months of follow-up [44]. Urinary retention last-
ing for 2 weeks and flank pain from vesicoureteric reflux occurred
in 1 female and 1 male, respectively. The advantage of this thera-
peutic option is the direct action on the target organ, thus avoiding
the systemic side effects of oral anticholinergic therapy such as
heat intolerance and constipation. The disadvantages are the lack of
long-term efficacy and requirement of general anesthesia.
Another non-pharmacologic approach to the treatment of overactive
bladder is neuromodulation. Although the therapeutic mechanism
is not entirely understood, the stimulation of afferent sacral nerve
fibers in the S2-S4 region is believed to inhibit supraspinally medi-
ated signals leading to detrusor overactivity [45]. In children with
detrusor overactivity, stimulation of these fibers can occur via
transcutaneous or, much less commonly, direct stimulation of the
parasacral nerves [46–49]. For parasacral transcutaneous electri-
cal nerve stimulation (TENS), patch electrodes placed in the sacral
region are attached to a frequency generator with stimulation applied
for 20–120 min. The optimal therapy is difficult to determine as the
published studies show significant variation in frequencies applied
(2–150 Hz), the duration (20–120 min) and occurrence (twice daily
to once per week) of each therapeutic session, as well as the num-
ber of months (1–6) TENS was utilized. Nevertheless, 47–62% of
subjects report resolution of their symptoms [47,50,51]. By stim-
ulating a peripheral sensory nerve whose roots are located in the
L4-S3 region, posterior tibial nerve stimulation (PTNS) is felt to
centrally inhibit pregangionic bladder motor neurons in the sacral
spinal cord [52]. PTNS uses a pulse generator to stimulate patch
electrodes placed superior to the medial malleolus. One group found
a 41% and 71% resolution rate in overactive bladder and dysfunc-
tional voiding, which improved significantly with a second PTNS
cycle [53]. Barroso compared parasacral TENS to PTNS, and found
70% and 9% complete resolution in the TENS and PTNS groups,
respectively [54]. Importantly, the methodology varied significantly
between the two groups (i.e. stimulation frequencies, session dura-
tion, and number of times per week for each session favored the
TENS group), and the authors’ conclusion that parasacral TENS
is more effective may be overstated. As many of the studies for
TENS and PTNS report only results while on therapy, the long-
term cure rates for these modalities are not well described. One study
suggested that as many as 50% of patients will require chronic tran-
scutaneous therapy [53]. When a stimulator is implanted, cure rates
for full response are 40% and partial response are 33% at 2 years of
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ollow-up [49]. Another study found significant improvements in
ealth related quality of life scores after a median 6-month follow-
p after the permanent stimulator was placed [46]. In summary, if
amilies are motivated, willing and able to undergo chronic therapy,
euromodulation has acceptable rates of symptomatic improvement
or children with nonneurogenic incontinence.
. Nocturnal  enuresis
hree conditions are felt to contribute to nocturnal enuresis –
mpaired sleep arousal threshold, nocturnal polyuria, and detrusor
veractivity [3–5]. This knowledge helps the practitioner under-
tand the different treatment modalities available for their enuretic
atient. Importantly, experts recognize that a significant portion
f monosymptomatic enuresis patients likely have underreported
r underdiagnosed daytime symptoms, thus explaining the over-
apping therapeutic efficacy in many patients. As the therapy for
on-monosymptomatic enuresis incorporates strategies used for
aytime incontinence and monosympotmatic enuresis, this section
ill focus primarily on monosymptomatic enuresis.
fter excluding underlying medical conditions and undertaking
n appropriate evaluation to exclude relevant comorbid condi-
ions, the ICCS recommends a stepwise approach to treatment of
onosymptomatic enuresis [55]. Prior to instituting any urother-
py, the practitioner should assess and treat constipation. The family
hould assess nocturnal urine production by weighing diapers and
easuring voided volumes during normal feeding and drinking.
hen present, nocturnal polyuria, defined as urine volumes greater
han 130% of expected bladder capacity for age [55], can help direct
he practioner towards desomopressin therapy.
hen first presented with an enuretic patient, education and sim-
le behavior maneuvers should be employed. Patients and families
hould be educated about normal bladder function and be instructed
o void regularly throughout the day, immediately before bed-
ime, and on awakening. The majority of fluid intake should occur
hroughout the morning and afternoon with minimal drinking in the
vening hours. Other simple measures such as reward systems for
ry nights can be instituted. Compared to controls, children who
nderwent the above behavioral therapies were found to have fewer
et nights and lower relapse rates [56]. However, both the response
nd relapse rate are inferior compared to enuresis alarms and drug
herapy.
larm therapy is the mainstay of treatment for enuresis in those
ho do not respond to education and simple behavior maneuvers.
laced under the bed linens or applied to the undergarments, the
larm senses wetness and arouses the patient with an audible or
ibratory alarm. An adequate understanding of the technology and
eatures of the device by motivated caregivers is required during the
 to 6 month therapy period. A systematic review of 3.257 children
rom 56 randomized trials found that two-thirds of patients become
ry while using the alarm, thus making it an excellent first line thera-
eutic option [57]. Of those who become dry on therapy, nearly half
ill relapse. Several options exist for those that relapse, including
verlearning and repeating another course of treatment. Overlearn-
ng is the process whereby newly dry patients are given extra fluids
rior to bedtime while still using the device, and has been shown
o lower relapse rates. Some advocate that adding desmopressin to
larm therapy improves response in those that failed, although the
ata is conflicting [58,59].
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esmopressin (DDAVP) is a vasopressin analogue with an antidi-
retic effect and represents another good first line therapy option.
he ICCS suggest that the best candidates for this therapy are those
ith nocturnal urine production > 130% of expected bladder capac-
ty for age (nocturnal polyuria) who are able to void at least 70%
f their expected bladder capacity [55]. While actively taking the
edication, 30 and 40% of children are estimated to be full and
artial responders, respectively, with about 1.3 fewer wet nights per
eek expected [55,60]. Formerly indicated for primary nocturnal
nuresis, intranasal DDAVP is no longer recommended given the
isk of hyponatremia-related seizure events. Tablets are available in
.2 and 0.4 mg doses and should be given at least 1 h before bed-
ime. There are no clear dose-related effects [60]. The medication is
ell tolerated with the only notable but significant risk being water
ntoxication causing hyponatremia and seizures in those who ingest
xcessive fluid prior to bed. Therefore, fluids should be restricted
o 200 ml (6 oz) or less during the evening. As there was no differ-
nce in wet nights after cessation of therapy comparing treatment to
lacebo [60], desmopressin does not cure enuresis. However, given
he favorable side effect profile and cost notwithstanding, the med-
cation can be continued until short periods of abstinence show the
hild to be dry.
f the tricyclic antidepressants (TCA), imipramine is historically
he most commonly used in enuresis treatment. In addition to its
eripheral anticholinergic effects, it acts centrally to increase vaso-
ressin release and modify the sleep arousal pattern [61,62]. For
nuresis, the doses (given at bedtime) are 25 mg for patients younger
nd 50 mg for patients older than 9 years. Side effects of imipramine
nclude typical anticholinergic effects such as dry mouth and con-
tipation, and mood changes and insomnia have been reported in
hildren taking it for enuresis. At high doses, imipramine is car-
iotoxic, so its use in those with long QT syndrome or a family
istory of sudden cardiac death should be avoided. Therapy should
e interrupted every three months to avoid tachyphylaxis. One-fifth
f children become dry while receiving TCA therapy for enuresis,
hough like desmopressin all patients relapse after cessation [63]. No
vidence favors desmopressin compared to TCAs [60]. Although the
ide effect profile favors desmopressin, the lower cost of imipramine
ay make it more attractive to some families.
he ICCS also recommends a stepwise strategy to treat NMNE:
ddress constipation, if present; diagnose and treat daytime LUTS;
dentify if comorbid behavioral disorders are present and refer for
reatment; apply standard therapy for monosymptomatic noctur-
al enuresis [64]. This strategy recognizes that with successful
reatment of preceding steps, improvement or cure of nighttime
ymptoms is possible. The diagnostic and treatment strategies out-
ined for constipation, daytime incontinence, and monosymptomatic
octurnal enuresis should be employed for patients suffering from
onmonosymptomatic nocturnal enuresis.
eurogenic incontinence
atients with neurogenic incontinence will have leakage as a result
f detrusor overactivity causing elevations in intravesical pressure
bove the urethral outlet resistance (a so-called upper motor neuron
esion) and/or from an incompetent external urethral sphincter (a so-
alled lower motor neuron lesion). Importantly, some children will
e found to have both causes for incontinence. This determination
s made through a full urodynamic study with cystometry. Other
mportant parameters measured on UDS are the bladder capacity,
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hich may not provide an adequate reservoir for urine storage, and
he intravesical storage pressures, which if high can lead to renal
eterioration. The principles of incontinence treatment for neuro-
enic bladder are the same irrespective of the etiology of the lesion.
hat is, upper motor neuron lesions causing detrusor overactivity
rom traumatic spinal cord injury or myelodysplasia are treated in
he same manner. As such, this section focuses on general strate-
ies to treat incontinence. It does not discuss specific etiologies and
ecognizes that lesions evolve and new symptoms in a formerly sta-
le patient should prompt repeat urodynamic studies. Finally, while
he maintenance of low intravesical storage pressures is of utmost
mportance for renal preservation, it will not be discussed here.
lean intermittent catheterization (CIC) enables efficient and com-
lete bladder emptying in patients with neurogenic bladder who
re unable to spontaneously void yet suffer from spontaneous unin-
ibited bladder contractions causing incontinence. The frequency of
atheterization can be adjusted to maintain dryness in these patients.
ollowing CIC, anticholinergics are the mainstay of pharmacologic
reatment for neurogenic urinary incontinence caused by detrusor
veractivity (Table 1). Establishing a good bowel regimen prior to
nstituting anticholinergic therapy is of utmost importance in this
opulation that is particularly susceptible to constipation. The anti-
holinergic doses used to treat neurogenic incontinence may be
igher than those needed in non-neurogenic incontinence. If patients
o not respond to a particular medication, its dose can be increased
r an alternative anticholinergic tried.
nabotulinum toxin – type A (BTX-A, Botox) has been used in
atients with neurogenic bladder who are either non-compliant with
r resistant to anticholinergic therapy. Although there are no ran-
omized controlled trials comparing BTX-A to placebo or other
herapeutics, a review of six observational studies using BTX-A in
ostly myelodysplastic patients found 65–87% of patients becom-
ng completely dry after injections, with significant improvements
n detrusor storage pressures and bladder compliance [41]. Marte’s
ore recent study presented similar results, with 81% of children
ecoming completely dry between catheterizations [65]. Although
o deaths or significant systemic adverse effects have been noted
hen using BTX-A for pediatric urology indications, patients can
xperience transient hematuria, UTIs, urinary retention, or persistent
ank pain following injections [41,44,65]. BTX-A is a temporary
eurolytic: patients who initially respond to therapy will experience
 loss of therapeutic efficacy and require repeat injections after 3
o 12 months [42–44,65]. Though not FDA approved in the pedi-
tric population, BTX-A has been shown to improve bladder storage
haracteristics and improve continence in patients with neurogenic
tiologies.
eurostimulation has been used with limited success in patients with
eurogenic incontinence. Capitanucci reported improvements in
UTS in only 1/7 (14%) patients who completed the 12 week poste-
ior tibial nerve stimulation cycle. No patients were cured, and many
ropped out of the study due to lack of subjective improvement.
uys randomized children with NGB to receive either sacral neu-
omodulation or standard therapy with anticholinergic and bladder
eck bulking agents [66]. Sacral neuromodulation was performed
n the same fashion as in adults with continuous stimulation of the
3 nerve root via an implantable nerve stimulator. At 12 months
ompliance, bladder filling pressures, and post-void residuals were
he same between the two groups, though the conventional ther-
py group had greater improvements in bladder capacity and the
ut
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neuromodulation group had greater improvements in detrusor leak
point pressures. Xiao described an invasive neurosurgical procedure
in which a lumbar ventral nerve is re-routed to the sacral nerves
to provide a new skin to central nervous system to bladder path-
way that facilitates bladder emptying [67]. Twelve of 14 (86%) of
patients with areflexic NGB had clinically significant improvements
in bladder capacity and maximal detrusor pressure at 12 months of
follow-up. Improvements from hostile bladder dynamics to near
normal urodynamic profiles were seen in 5 of 6 (83%) patients
with preoperative detrusor hyperreflexia and/or detrusor-sphincter
dyssynergia. The results of clinical trials investigating the Xiao Pro-
cedure in the United States are forthcoming, and this procedure
should be deemed experimental until these and other studies confirm
the findings of Xiao.
Although CIC and anticholinergic medications are the mainstay
of treatment for bladder overactivity in the neurogenic population,
some patients on maximal anticholingergic doses will continue to
have high-pressure, small capacity, overactive bladders with result-
ing upper urinary tract changes and persistent incontinence. For
such patients, bladder augmentation with colon, small intestine, or,
infrequently, gastric segments can create a safe, low pressure uri-
nary storage reservoir. Results from several single institution series
with limited numbers of patients show significant improvements in
bladder capacity, detrusor leak point pressure, and continence rates
[68,69]. One study investigated the health related quality of life in
myelodysplastic patients, and found no improvements in patients’
quality of life after surgery compared to before surgery [70]. Finally,
it is important to recognize that the short- and long-term com-
plications of augmentation cystoplasty (ileus, bowel obstruction,
bladder stone formation, vitamin deficiency, metabolic acidosis
leading to bone demineralization and decreased linear bone growth,
and bladder perforation, among others) are significant and can be
life-threatening.
Some children with neurogenic incontinence will have an incom-
petent bladder outlet. In such patients, artificial urinary sphincters
(AUS), fascial slings, or bladder neck reconstructions can be used to
increase outlet resistance. Each option has its own unique attributes.
An AUS can maintain spontaneous voiding in certain children and
provide sufficient outlet resistance to improve incontinence. They
infrequently become infected or suffer erosions and are durable but
can require small revision surgeries owing to their mechanical nature
[71]. Autologous rectus fascia or small intestinal submucosa blad-
der neck slings and wraps have been successfully used in patients
with neurogenic sphincteric incontinence [72,73]. In patients with
bladder augmentations, slings provide the advantage of preserving
the urethra as a pop-off mechanism and negate the complexity and
low but present infectious risk of the AUS. However, children with
fascial slings may not be able to spontaneously void. Several vari-
ations of the bladder neck reconstruction exist, and common to all
are urethral elongation and reliance on either increased muscular
backing or the Mitrofanoff principle to improve continence. These
operations are seldom used in this population for several reasons:
their creation uses precious bladder capacity, catherization can be
difficult, and they often do not provide adequate increases in outlet
resistance sufficient for continence.Anatomic incontinence
Treating anatomically related incontinence with surgery can be one
of the most satisfying and challenging operations for a pediatric
d
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rologist. Although a thorough description of technique is outside
he scope of this article, we briefly discuss the surgical strategies
sed in some of these conditions.
hen an ectopic ureter is suspected in a female with continuous
ncontinence and verified by radiologic workup, surgical therapy can
rovide a cure. If a renal scan confirms a poorly functioning upper
ole segment drained by the ectopic ureter, a partial nephrectomy
ith excision of the ureter as far distally as possible will provide
mmediate dryness. Alternatively, if the functioning segment con-
ributes significantly to renal function, it should be preserved. The
resence or absence of lower pole vesicoureteral relux will deter-
ine the surgical approach. If reflux is present, a common sheath
reteral reimplantation is a viable option. If reflux is absent, an upper
o lower pole ureteroureterostomy or pyeloureterostomy redirects
pper pole urine drainage to the non-refluxing lower pole ureter,
hus curing continuous incontinence.
hildren with bladder exstrophy or epispadias will require surgery
o reconstruct the urethra and bladder neck. Several different
echniques are described, though all have the common goals of
reserving upper tract function, providing cosmetically pleasing
nd functional external genitalia, and achieving urinary continence.
s the initial bladder closure often fails to provide adequate out-
et resistance, a bladder neck reconstruction is used to create outlet
esistance sufficient for continence but still allow spontaneous void-
ng.
here are other rare etiologies of anatomic urinary incontinence
uch as cloacal anomalies and urethral duplications which require
ndividualized surgical approaches. A good preoperative workup
ncluding diagnostic imaging and cystoscopy will help define the
ongenital anomaly and aid the surgeon in reconstructing normal
natomy.
onclusion
ediatric urinary incontinence is a common condition. A thor-
ugh history and systematic physical exam will direct the provider
owards adjunctive tests, if required. Identification of the parents’
otivation and goals for their child’s treatment will help the clini-
ian form a management plan and set reasonable expectations. The
dentification and treatment of constipation is of utmost importance
rior to beginning incontinence therapy. If classified as having day-
ime incontinence, a stepwise approach beginning with behavioral
nd biofeedback therapy prior to instituting anticholinergic medi-
ation should be followed. An evidence-based approach to enuresis
uggests that alarm therapy in a household with motivated caregivers
ill provide durable cures in a majority of children. Although the
elapse rates are high for enuretic children on pharmacotherapy,
esmopressin and amitryptyline decrease wet nights when the child
akes them routinely, and provide a good option for special events
ike vacations or sleep-overs. Identification of bladder overactivity
nd/or sphincteric deficiency helps direct the management plan for
eurogenic incontinence. The former is often successfully treated
ith CIC and anticholinergic therapy; augmentation cystoplasty is
eserved for patients with high bladder storage pressures and rela-
ively small bladder capacities who continue to leak despite maximal
ose anticholinergics. Surgery to increase bladder outlet resistance is
sed to treat the latter patients with sphincteric deficiency. Surgery is
lso the mainstay of treatment for those children with a well-defined
natomic etiology for their incontinence.
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